Managing ART Failure: Answering the Questions

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:The definitions of virologic blips, low-level viremia, and virologic failure on ARTThe infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real worldThe potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factorsThe impact of adherence on viral suppression with BIC- and DTG-based ARTDrug-drug interactions as a reason for failure of first-line INSTI-based ARTWhat to do if someone is experiencing virologic failure requiring an ART changeThe use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experienceThe impact of high HIV-1 RNA on ART effectivenessThe impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ARTStrategies to encourage and measure patient adherence to ART PresentersDaniel R. Kuritzkes, MD<br />Harriet Ryan Albee Professor of Medicine<br />Harvard Medical School<br />Chief, Division of Infectious Diseases<br />Brigham and Women’s Hospital<br />Boston, MassachusettsCristina Mussini, MD<br />Professor<br />Department of Infectious Diseases<br />University of Modena and <br />Reggio Emilia<br />Modena, ItalyLink to full program: https://bit.ly/3HPu4Lk